BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
-11.11%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.07B
AUM Growth
-$1.54B
(-18%)
Cap. Flow
-$234M
Cap. Flow
% of AUM
-3.31%
Top 10 Holdings %
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$58.1M |
| 2 |
Pfizer
PFE
|
$41.4M |
| 3 |
Harmony Biosciences
HRMY
|
$28.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$25.4M |
| 5 |
Celldex Therapeutics
CLDX
|
$24.9M |
Top Sells
| 1 |
Elevance Health
ELV
|
$98M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$85.7M |
| 3 |
AbbVie
ABBV
|
$47.7M |
| 4 |
Bristol-Myers Squibb
BMY
|
$46.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$42.9M |
Sector Composition
| 1 | Healthcare | 98.26% |
| 2 | Industrials | 0.38% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
10x Genomics
TXG
$1.64B
| $11.7M | 0.17% |
259,371
+6,512
| +3% | +$295K |
|
|
NVRO
102
DELISTED
NEVRO CORP.
NVRO
| $11.6M | 0.16% |
265,339
+27,498
| +12% | +$1.21M |
|
103
Black Diamond Therapeutics
BDTX
$162M
| $11.6M | 0.16% |
4,717,113
+1,424,113
| +43% | +$3.5M |
|
|
104
Regeneron Pharmaceuticals
REGN
$60.8B
| $10.5M | 0.15% |
17,727
-72,553
| -80% | -$42.9M |
|
|
MTEM
105
DELISTED
Molecular Templates, Inc.
MTEM
| $10.3M | 0.15% |
751,867
+13,333
| +2% | +$182K |
|
|
SGEN
106
DELISTED
Seagen Inc. Common Stock
SGEN
| $8.74M | 0.12% |
49,376
-1,024
| -2% | -$181K |
|
107
American Well
AMWL
$108M
| $7.65M | 0.11% |
88,485
| – | – |
|
|
ONEM
108
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $6.56M | 0.09% |
836,190
| – | – |
|
109
Health Catalyst
HCAT
$224M
| $6.15M | 0.09% |
424,611
| – | – |
|
110
BioMarin Pharmaceuticals
BMRN
$11B
| $6.11M | 0.09% |
73,753
-847
| -1% | -$70.2K |
|
111
AstraZeneca
AZN
$254B
| $5.75M | 0.08% |
87,000
-2,600
| -3% | -$172K |
|
112
Johnson & Johnson
JNJ
$429B
| $5.13M | 0.07% |
28,914
+1,214
| +4% | +$216K |
|
113
Doximity
DOCS
$12.6B
| $4.75M | 0.07% |
136,322
+53,462
| +65% | +$1.86M |
|
114
Gilead Sciences
GILD
$141B
| $4.66M | 0.07% |
75,426
-8,024
| -10% | -$496K |
|
115
Biogen
BIIB
$20.3B
| $4.46M | 0.06% |
21,850
-500
| -2% | -$102K |
|
|
OLK
116
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $3.58M | 0.05% |
235,273
| – | – |
|
117
Q32 Bio
QTTB
$20.5M
| $3.2M | 0.05% |
90,140
-1,367
| -1% | -$48.5K |
|
118
Alkermes
ALKS
$4.79B
| $3.19M | 0.05% |
107,200
+32,200
| +43% | +$959K |
|
119
Pacira BioSciences
PCRX
$1.21B
| $3.03M | 0.04% |
51,936
+30,800
| +146% | +$1.8M |
|
120
Guardant Health
GH
$7.35B
| $2.85M | 0.04% |
70,580
-139,132
| -66% | -$5.61M |
|
121
Sight Sciences
SGHT
$196M
| $2.65M | 0.04% |
294,606
-5,394
| -2% | -$48.5K |
|
122
Cytokinetics
CYTK
$6.07B
| $2.61M | 0.04% |
66,400
-2,600
| -4% | -$102K |
|
123
Pulmonx
LUNG
$66M
| $2.55M | 0.04% |
173,336
-3,174
| -2% | -$46.7K |
|
124
Neuropace
NPCE
$317M
| $2.51M | 0.04% |
507,930
| – | – |
|
125
Supernus Pharmaceuticals
SUPN
$2.52B
| $2.38M | 0.03% |
82,400
+23,400
| +40% | +$677K |
|